Adrian Quartel
Chief Tech/Sci/R&D Officer chez ZEVRA THERAPEUTICS, INC.
Profil
Adrian Quartel is a professional with a doctorate degree from Erasmus University Rotterdam.
He is currently the Chief Medical Officer at Zevra Therapeutics, Inc. He previously held the position of Head-Medical Affairs at BioMarin Pharmaceutical, Inc. from 2017 to 2020 and was the Chief Medical Officer at Adamas Pharmaceuticals LLC from 2020 to 2022.
Dr. Quartel also served as the Chief Medical Officer at Acer Therapeutics, Inc.
Postes actifs de Adrian Quartel
| Sociétés | Poste | Début |
|---|---|---|
| ZEVRA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 04/01/2024 |
Anciens postes connus de Adrian Quartel
| Sociétés | Poste | Fin |
|---|---|---|
| ADAMAS PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/02/2022 |
| BIOMARIN PHARMACEUTICAL INC. | Chief Tech/Sci/R&D Officer | 01/09/2020 |
| ACER THERAPEUTICS INC. | Chief Tech/Sci/R&D Officer | - |
Formation de Adrian Quartel
| Erasmus University Rotterdam | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| ZEVRA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Adamas Pharmaceuticals LLC
 Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. | Health Technology |
Acer Therapeutics, Inc.
 Acer Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Acer Therapeutics, Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of therapies for medical needs. Its product pipeline includes Olpruva, Edsivo, and ACER-801. Olpruva is used for the treatment of urea cycle disorders. Edsivo is a type of celiprolol used in treating Vascular Ehlers-Danlos syndrome. ACER-001 treats menopausal related Vasomotor symptoms. The company was founded by Chris Schelling on March 15, 1991 and is headquartered in Newton, MA. | Health Technology |
